95 related articles for article (PubMed ID: 10706127)
21. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
[TBL] [Abstract][Full Text] [Related]
22.
Huszno J; Grzybowska E
Oncol Lett; 2018 Jul; 16(1):34-40. PubMed ID: 29928384
[TBL] [Abstract][Full Text] [Related]
23. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
24. c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC.
Ke L; Xiang Y; Guo X; Lu J; Xia W; Yu Y; Peng Y; Wang L; Wang G; Ye Y; Yang J; Liang H; Kang T; Lv X
Oncotarget; 2016 May; 7(19):28340-55. PubMed ID: 27078847
[TBL] [Abstract][Full Text] [Related]
25. Liprin-α1 is a regulator of vimentin intermediate filament network in the cancer cell adhesion machinery.
Pehkonen H; von Nandelstadh P; Karhemo PR; Lepikhova T; Grenman R; Lehti K; Monni O
Sci Rep; 2016 Apr; 6():24486. PubMed ID: 27075696
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
27. FGFR1 is an adverse outcome indicator for luminal A breast cancers.
Shi YJ; Tsang JY; Ni YB; Chan SK; Chan KF; Tse GM
Oncotarget; 2016 Jan; 7(4):5063-73. PubMed ID: 26673008
[TBL] [Abstract][Full Text] [Related]
28. Multiple gene aberrations and breast cancer: lessons from super-responders.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
[TBL] [Abstract][Full Text] [Related]
29. Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.
Beca F; Pereira M; Cameselle-Teijeiro JF; Martins D; Schmitt F
BMC Cancer; 2015 Apr; 15():285. PubMed ID: 25879784
[TBL] [Abstract][Full Text] [Related]
30. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
Liu S; Wang H; Zhang L; Tang C; Jones L; Ye H; Ban L; Wang A; Liu Z; Lou F; Zhang D; Sun H; Dong H; Zhang G; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Huang XF; Chen SY; Zhou T
Hum Genomics; 2015 Feb; 9(1):2. PubMed ID: 25757876
[TBL] [Abstract][Full Text] [Related]
31. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
André F; Cortés J
Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
[TBL] [Abstract][Full Text] [Related]
32. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Wheler JJ; Moulder SL; Naing A; Janku F; Piha-Paul SA; Falchook GS; Zinner R; Tsimberidou AM; Fu S; Hong DS; Atkins JT; Yelensky R; Stephens PJ; Kurzrock R
Oncotarget; 2014 May; 5(10):3029-38. PubMed ID: 24912489
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification.
Tabarestani S; Ghaderian SM; Rezvani H; Mirfakhraie R; Ebrahimi A; Attarian H; Rafat J; Ghadyani M; Alavi HA; Kamalian N; Rakhsha A; Azargashb E
Cell Oncol (Dordr); 2014 Apr; 37(2):107-18. PubMed ID: 24573687
[TBL] [Abstract][Full Text] [Related]
34. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.
Tiong KH; Mah LY; Leong CO
Apoptosis; 2013 Dec; 18(12):1447-68. PubMed ID: 23900974
[TBL] [Abstract][Full Text] [Related]
35. From integrative genomics to therapeutic targets.
Natrajan R; Wilkerson P
Cancer Res; 2013 Jun; 73(12):3483-8. PubMed ID: 23740772
[TBL] [Abstract][Full Text] [Related]
36. Riparian ecosystems in human cancers.
Alfarouk KO; Ibrahim ME; Gatenby RA; Brown JS
Evol Appl; 2013 Jan; 6(1):46-53. PubMed ID: 23396634
[TBL] [Abstract][Full Text] [Related]
37. Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells.
Junk DJ; Cipriano R; Stampfer M; Jackson MW
PLoS One; 2013; 8(2):e53776. PubMed ID: 23390492
[TBL] [Abstract][Full Text] [Related]
38. Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
Kornegoor R; Moelans CB; Verschuur-Maes AH; Hogenes MC; de Bruin PC; Oudejans JJ; Marchionni L; van Diest PJ
Breast Cancer Res Treat; 2012 Aug; 135(1):49-58. PubMed ID: 22527098
[TBL] [Abstract][Full Text] [Related]
39. C-myc as a predictive marker for chemotherapy in metastatic breast cancer.
Todorović-Raković N; Nešković-Konstantinović Z; Nikolić-Vukosavljević D
Clin Exp Med; 2012 Dec; 12(4):217-23. PubMed ID: 22113465
[TBL] [Abstract][Full Text] [Related]
40. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
